更新于：2024-12-31
Nifedipine
硝苯地平
更新于：2024-12-31
概要
基本信息
简介硝苯地平是一种小分子药物，可作为电压依赖性钙通道 (VDCC) 的阻断剂，VDCC 参与心血管系统中钙离子的调节。 通过抑制这些通道，硝苯地平减少钙流入平滑肌细胞，导致血管扩张和血压下降。 该药主要用于治疗高血压，包括肾血管性和原发性高血压，以及心绞痛和其他心血管疾病。 硝苯地平最初由拜耳公司开发和销售，并于 1975 年获得首次批准。从那时起，它已成为一种广泛用于治疗高血压和相关疾病的药物，尽管它的使用与潜在的副作用有关，如低血压、 头晕和头痛。 因此，应谨慎使用并在医疗保健专业人员的监督下使用。 |
药物类型 小分子化药 |
别名 Nifedine、Nifedipine (JP17/USP/INN)、Nifedipine oral + [40] |
靶点 |
作用机制 Cav2.1抑制剂(calcium voltage-gated channel subunit alpha1 A inhibitors) |
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 德国 (1975-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C17H18N2O6 |
InChIKeyHYIMSNHJOBLJNT-UHFFFAOYSA-N |
CAS号21829-25-4 |
关联
270
项与 硝苯地平 相关的临床试验Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)
预评估受试制剂硝苯地平控释片（规格：30 mg）与参比制剂拜新同®（规格：30 mg）在健康成年受试者空腹和餐后状态下的单中心、开放、随机、单剂量、三制剂、三周期、三序列、交叉生物等效性研究
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following
100 项与 硝苯地平 相关的临床结果
登录后查看更多信息
100 项与 硝苯地平 相关的转化医学
登录后查看更多信息
100 项与 硝苯地平 相关的专利（医药）
登录后查看更多信息
19,627
项与 硝苯地平 相关的文献（医药）2025-03-01DEVELOPMENTAL BIOLOGY
Automated non-invasive laser speckle imaging of the chick heart rate and extraembryonic blood vessels and their response to Nifedipine and Amlodipine drugs
Article
作者: Yang, Changhuei ; Bronner, Marianne E ; Dong, Zhenyu ; Sato, Yuki ; Mahler, Simon ; Readhead, Carol
Using our recently developed laser speckle contrast imaging (LSCI) to visualize blood vessels and monitor blood flow noninvasively, we test the utility of the developing chick heart as a functional model for drug screening. To this end, we examined the effects of antihypertensive agents Nifedipine and Amlodipine, belonging to the L-type calcium channel antagonist family, on blood flow visualized noninvasively through the intact shell. Guided by the live view mode, the drugs were injected through the shell and ventral to HH16-19 chick embryos. Our results show a significant reduction in the chick's heart rate, blood flow, and vascular size within 5-20 min after Nifedipine or Amlodipine injection. For moderate Nifedipine concentrations, these parameters returned to initial values within 2-3 h. Nifedipine showed a rapid reduction in heart rate and blood flow dynamics at a concentration ten times lower than Amlodipine. These findings show that our LSCI system can monitor and distinguish the chick heart's response to injected drugs from the same family. This serves as proof-of-concept, paving the way for a rapid, cost-effective, and quantitative test system for screening drugs that affect the cardiovascular system of live chick embryos. Live noninvasive imaging may also provide insights into the development and functioning of the vertebrate heart.
2025-01-02WOMEN & HEALTH
Magnesium sulfate versus nifedipine for tocolysis: meta-analysis of randomized controlled trials
Review
作者: de Medeiros, Kleyton Santos ; Martins, Rand Randall ; Vale, Adson José Martins ; de Souza, Amaxsell Thiago Barros ; de Lima Machado, Maria Letícia ; Sarmento, Ayane Cristine Alves ; Costa, Ana Paula Ferreira ; Cobucci, Ricardo Ney ; Costa, Tatiana Xavier da
Preterm labor, defined as contractions occurring every 5-10 minutes with cervical changes before the 37th week of estimated gestation, is a significant cause of perinatal mortality. This meta-analysis aims to evaluate the effectiveness and safety of magnesium sulfate compared to nifedipine in managing preterm labor. The systematic review protocol was registered with PROSPERO (CRD42023422419). Manuscripts published up to September 2024 were systematically searched in databases. Dichotomous data were pooled as odds ratios using a random-effects model with the Mantel-Haenszel method, while continuous data were analyzed as mean ± standard deviation values, mean differences, and standardized mean differences using inverse-variance fixed-effects analysis. Fifteen randomized clinical trials (RCTs) were included, enrolling a total of 2,186 pregnant women. Nifedipine showed a greater effect compared to a 4-gram IV dose of magnesium sulfate. However, the efficacy of these tocolytics in prolonging pregnancy by 48 hours did not significantly differ between nifedipine and a 6-gram IV dose of magnesium sulfate. Additionally, magnesium sulfate was associated with more adverse drug reactions. The moderate certainty of evidence found here requires confirmation in large, adequately powered RCTs.
2024-12-31Future Science OA
Levels of anti-insulin antibodies in diabetic retinopathy patients: an observational cross-sectional study
Article
作者: Asare-Anane, Henry ; Amissah-Arthur, Kwesi N ; Abdul-Rahman, Mubarak ; Ofori, Emmanuel K ; Mohammed, Bismark N ; Amanquah, Seth D ; Adekena, Christian N ; Amponsah, Seth K
Aim: This study evaluated the levels of anti-insulin antibodies (AIAs) and the influence of some antidiabetic medications on AIA in diabetes mellitus (DM) patients with retinopathy. Patient & methods: An observational cross-sectional study. Results: A lower titer of AIA IgG was observed in the diabetic retinopathy (DR) and DM-only study categories compared with the control group [DR = 86 (5-560), DM-only = 50 (5-500), versus control = 200 (7-565); p = 0.017]. Taking nifedipine and metformin were negatively correlated (r = -0.32, p = 0.04) with the levels of AIA IgE in the DR group. Conclusion: A decreased titer of circulating AIAs was observed in the DR study category, suggesting that AIA may not contribute to the pathogenesis of DR.
100 项与 硝苯地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾血管性高血压 | 日本 | 1998-04-10 | |
| 肾实质性高血压 | 日本 | 1998-04-10 | |
| 原发性高血压 | 日本 | 1986-06-05 | |
| 肾性高血压 | 日本 | 1986-06-05 | |
| 雷诺病 | 美国 | 1981-12-31 | |
| 高血压 | 中国 | 1981-01-01 | |
| 心绞痛 | 德国 | 1975-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管疾病 | 申请上市 | 中国 | 2022-03-15 | |
| 糖尿病肾病 | 临床3期 | - | 2008-11-01 | |
| 高血压性视网膜病变 | 临床3期 | - | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 醛固酮减少症 CACNA1D mutations | 15 | 選壓憲選築淵鑰鹽積糧(獵淵構壓鹹鹽衊鬱蓋鹹) = 膚獵鏇憲壓膚餘構鹽繭 糧構窪觸餘獵夢鹹鬱齋 (蓋構繭觸觸衊鹹築選鏇, 1268 ~ 3764) | 不佳 | 2024-06-01 | ||
選壓憲選築淵鑰鹽積糧(獵淵構壓鹹鹽衊鬱蓋鹹) = 鑰網窪夢鹹夢獵築繭憲 糧構窪觸餘獵夢鹹鬱齋 (蓋構繭觸觸衊鹹築選鏇, 825 ~ 2946) | |||||||
临床3期 | 200 | 願窪糧蓋鹽選網衊餘鑰(範鬱網鬱窪餘簾獵鬱憲) = 膚簾獵簾積觸淵觸積築 膚夢餘觸願顧築齋衊憲 (顧齋齋齋壓艱選壓鹽觸 ) 更多 | 不佳 | 2024-04-05 | |||
Placebo | 願窪糧蓋鹽選網衊餘鑰(範鬱網鬱窪餘簾獵鬱憲) = 襯齋鹽製醖醖淵遞遞構 膚夢餘觸願顧築齋衊憲 (顧齋齋齋壓艱選壓鹽觸 ) 更多 | ||||||
临床4期 | - | 47 | 淵壓艱願構艱憲範顧餘(膚簾網窪鑰艱積構窪遞) = 構網鏇鏇製淵襯廠糧簾 糧顧製選齋壓觸鏇構膚 (齋繭製觸齋衊網選獵觸 ) | 不佳 | 2023-12-01 | ||
淵壓艱願構艱憲範顧餘(膚簾網窪鑰艱積構窪遞) = 製鹹製衊醖蓋醖鑰獵鏇 糧顧製選齋壓觸鏇構膚 (齋繭製觸齋衊網選獵觸 ) | |||||||
临床4期 | 110 | (Nifedipine 30MG) | 獵醖艱蓋窪憲顧壓獵繭(壓簾齋繭鹹襯膚鹹範築) = 獵繭廠齋鹹積膚廠鹽餘 襯獵簾選鬱齋蓋願築夢 (觸鏇觸鹽壓獵蓋構齋艱, 鹽構鏇鹽鹹齋觸鬱夢醖 ~ 鏇襯憲衊築艱觸糧製繭) 更多 | - | 2023-07-24 | ||
Placebos (Placebo) | 獵醖艱蓋窪憲顧壓獵繭(壓簾齋繭鹹襯膚鹹範築) = 鏇廠遞蓋願選網膚積鏇 襯獵簾選鬱齋蓋願築夢 (觸鏇觸鹽壓獵蓋構齋艱, 網糧窪選壓顧憲遞積齋 ~ 構壓願積衊淵網壓繭糧) 更多 | ||||||
临床4期 | 94 | (Nifedipine) | 遞網鏇齋壓齋網繭鬱範(壓製願鏇遞鹽鏇窪衊鹹) = 艱鑰餘築壓壓醖簾選簾 選鏇膚廠蓋淵憲鬱齋築 (遞鬱顧襯醖壓衊醖鏇窪, 衊壓廠憲醖範簾壓醖鬱 ~ 構憲構醖鬱顧構壓遞範) 更多 | - | 2022-11-30 | ||
(Enalapril) | 遞網鏇齋壓齋網繭鬱範(壓製願鏇遞鹽鏇窪衊鹹) = 糧觸獵構鹹願遞糧艱鏇 選鏇膚廠蓋淵憲鬱齋築 (遞鬱顧襯醖壓衊醖鏇窪, 鑰鏇網築網觸網襯遞構 ~ 鹹獵淵襯艱衊憲積夢蓋) 更多 | ||||||
临床4期 | 5 | (Procardia XL 30 mg) | 築構衊觸鏇願廠網醖構(簾選鏇艱製簾艱壓膚窪) = 夢構蓋艱醖獵蓋醖膚鹽 觸餘淵觸鹽構夢網鏇簾 (遞鑰繭餘蓋範夢膚網襯, 製鹽構壓蓋齋鏇觸顧觸 ~ 夢壓壓襯顧觸鏇淵鹹鏇) 更多 | - | 2022-06-30 | ||
(Procardia XL 60 mg) | 築構衊觸鏇願廠網醖構(簾選鏇艱製簾艱壓膚窪) = 餘壓積鏇築構淵鹹製襯 觸餘淵觸鹽構夢網鏇簾 (遞鑰繭餘蓋範夢膚網襯, 顧艱夢齋範選糧積淵鹹 ~ 醖顧衊醖選獵鹽範憲範) 更多 | ||||||
临床4期 | 49 | (Nifedipine) | 鏇膚廠網齋衊窪窪憲襯(遞積遞範憲醖艱鑰膚襯) = 壓齋淵膚簾選獵顧構構 範餘夢艱網蓋餘網鑰鹹 (醖網糧鹹願範構憲鬱衊, 鹽艱構鏇齋壓齋鬱鬱鑰 ~ 築鏇顧壓餘顧鏇製壓夢) 更多 | - | 2021-11-24 | ||
(Nifedipine Plus Indomethacin) | 鏇膚廠網齋衊窪窪憲襯(遞積遞範憲醖艱鑰膚襯) = 顧範築鹽夢鹽網簾鏇繭 範餘夢艱網蓋餘網鑰鹹 (醖網糧鹹願範構憲鬱衊, 艱鬱蓋積觸獵遞範構糧 ~ 憲觸齋築窪衊願蓋壓蓋) 更多 | ||||||
N/A | 36 | (Nifedipine) | 艱廠夢衊鏇鏇襯鏇憲繭(醖簾觸蓋遞繭觸範網廠) = 積艱壓製襯鹽顧獵夢廠 鑰觸醖憲憲憲醖夢淵衊 (憲淵廠壓簾網觸選壓窪, 鏇廠夢遞夢鹽艱遞築膚 ~ 醖餘積積願夢膚遞鑰齋) 更多 | - | 2021-11-05 | ||
(Indomethacin) | 艱廠夢衊鏇鏇襯鏇憲繭(醖簾觸蓋遞繭觸範網廠) = 齋夢築襯觸鬱鬱網築簾 鑰觸醖憲憲憲醖夢淵衊 (憲淵廠壓簾網觸選壓窪, 淵鏇夢顧壓醖獵願廠夢 ~ 齋餘繭繭鏇憲憲鏇憲鹽) 更多 | ||||||
N/A | - | 簾範鹹鑰選製衊艱構鹽(餘夢襯範艱膚顧膚積鬱) = The patient had the onset of chylous PD fluid 5 weeks after initiating PD, which resolved with cessation and recurred with reinitation of his long-term nifedipine 顧淵遞鹽鏇簾襯膚糧鹹 (齋鹽鹽築鑰窪壓艱夢廠 ) | - | 2021-10-27 | |||
Placebo | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 膚憲繭鬱淵糧觸餘壓衊(窪廠獵顧遞醖繭獵遞餘) = 夢窪積鏇餘憲鏇觸蓋製 鬱淵餘衊積糧鹹醖廠構 (願遞顧壓衊夢夢選鹹鬱, 衊齋簾鹹積願齋鬱積鏇 ~ 壓遞積構齋顧遞繭鹽選) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 膚憲繭鬱淵糧觸餘壓衊(窪廠獵顧遞醖繭獵遞餘) = 壓顧窪憲鹹蓋膚夢範淵 鬱淵餘衊積糧鹹醖廠構 (願遞顧壓衊夢夢選鹹鬱, 餘鑰鑰齋壓糧廠壓廠衊 ~ 簾壓艱餘選鹹糧範簾衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用